Skip to Main Content

A California biotech announced itself to the world on Monday with $275 million, a familiar name at the top  — and no pipeline in sight.

The company, Nuvation Bio, aims to be ambitious — according to the press release announcing the round, it has seven “mechanistically distinct programs.” It did not disclose any details about what those programs are, however. Nuvation’s CEO is Dr. David Hung.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!